The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
20 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $9,661,154 in first-year total cost, median $490,001.
Most frequent study sections
- Special Emphasis Panel[ZRG1 EMNR-B (50)]13
- Special Emphasis Panel[ZRG1 EMNR-F (50)]4
- Special Emphasis Panel[ZRG1-EMNR-B(50)R]2
- Special Emphasis Panel[ZRG1 EMNR-F (07)]1
Most frequent institutions
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2
- STANFORD UNIVERSITY2
- YALE UNIVERSITY2
- BETH ISRAEL DEACONESS MEDICAL CENTER1
- BRIGHAM AND WOMEN'S HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Novel therapeutic strategy for renal fibrosis by targeting RNA-binding protein HuR1R01DK123727-01 | HUANG, YUFENG | UNIVERSITY OF UTAH, UT | $366,700 | ZRG1 |
| 2020 | ENZYME THERAPY FOR CKD-MBD: BREAKING THE BARRIER OF VASCULAR CALCIFICATION1R01DK121326-01A1 | BRADDOCK, DEMETRIOS | YALE UNIVERSITY, CT | $238,800 | ZRG1 |
| 2019 | Small molecules targeting hepatic glucose production and insulin resistance1R01DK117655-01A1 | GRIFFIN, PATRICK ROBERTPUIGSERVER, PERE | DANA-FARBER CANCER INST, MA | $661,093 | ZRG1 |
| 2019 | Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates1R01DK119968-01 | SHULMAN, GERALD I | YALE UNIVERSITY, CT | $557,732 | ZRG1 |
| 2019 | The Development of TGR5 Antagonists for the Treatment of Cholangiopathies1R01DK117133-01A1 | LARUSSO, NICHOLAS F.OLSON, STEVEN H | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $537,612 | ZRG1 |
| 2019 | Small molecule inhibitors of LMPTP: an obesity drug target2R01DK106233-06 | BOTTINI, NUNZIOPINKERTON, ANTHONY BRUCE | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $518,066 | ZRG1 |
| 2019 | Development of Beta-Cell-Targeted Regenerative Therapeutics Using A Novel Prodrug Strategy1R01DK119955-01A1 | ANNES, JUSTIN PIERCE | STANFORD UNIVERSITY, CA | $426,790 | ZRG1 |
| 2019 | Optimization of Novel Small Molecules to Antagonize FGF-231R01DK121132-01 | QUARLES, L DARRYL | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $304,000 | ZRG1 |
| 2018 | Novel Selective Type II kinase Inhibitors to treat Diabetes1R01DK116904-01 | DEVITA, ROBERT JSTEWART, ANDREW F. | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $674,446 | ZRG1 |
| 2018 | Therapeutic Protein Engineering of Single-Chain Insulin Analogs1R01DK118536-01 | CHERRINGTON, ALAN DISMAIL-BEIGI, FARAMARZPHILLIPS, NELSON F BWEISS, MICHAEL AARON | INDIANA UNIVERSITY INDIANAPOLIS, IN | $554,879 | ZRG1 |
| 2018 | Developing UPR inhibitory KIRAs into oral antidiabetic beta cell-sparing drugs2R01DK100623-05 | BACKES, BRADLEY JMALY, DUSTIN JPAPA, FEROZ R | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $502,298 | ZRG1 |
| 2018 | Inhibiting Bcl-2-regulated intestinal fibrosis in models of Crohn’s Disease1R01DK118154-01 | HIGGINS, PETER D.R. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $467,340 | ZRG1 |
| 2018 | The Development of 4-methylumbelliferone Pro-drugs to Prevent Autoimmune Diabetes1R01DK114174-01A1 | BOLLYKY, PAUL L | STANFORD UNIVERSITY, CA | $419,389 | ZRG1 |
| 2018 | Targeting Diabetes With Novel SERCA Allosteric Activators1R01DK111417-01A1 | LEBECHE, DJAMEL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $381,375 | ZRG1 |
| 2018 | Preclinical therapeutic validation of a novel therapeutic lead for treating glomerular diseases such as focal and segmental glomerulosclerosis1R56DK116887-01A1 | NIHALANI, DEEPAKSCHNELLMANN, RICK G | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $100,000 | ZRG1 |
| 2017 | Preclinical Studies of Novel Anti-Diabetic Lipids1R56DK110150-01A1 | KAHN, BARBARA B.SAGHATELIAN, ALANSIEGEL, DIONICIO R | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $903,077 | ZRG1 |
| 2017 | L-Cystine Diamides as Inhibitors of L-Cystine Stone Formation in Cystinuria1R01DK112782-01 | HU, LONGQINSAHOTA, AMRIK | RUTGERS, THE STATE UNIV OF N.J., NJ | $621,145 | ZRG1 |
| 2017 | Targeting the orphan nuclear receptor LRH-1 with small molecules1R01DK115213-01 | CALVERT, JOHN WINTERJUI, NATHAN THOMASORTLUND, ERIC A | EMORY UNIVERSITY, GA | $490,001 | ZRG1 |
| 2017 | ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes1R01DK107239-01A1 | GRIFFIN, PATRICK ROBERTPLUTZKY, JORGE | BRIGHAM AND WOMEN'S HOSPITAL, MA | $490,000 | ZRG1 |
| 2017 | Relaxin receptor agonists for treatment of liver fibrosis1R01DK110167-01A1 | AGOULNIK, ALEXANDER I | FLORIDA INTERNATIONAL UNIVERSITY, FL | $446,411 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.